Copy For Citation
ILGIN S., Dagasan F., BURUKOĞLU DÖNMEZ D., BAYSAL M., ATLI EKLİOĞLU Ö.
ISTANBUL JOURNAL OF PHARMACY, vol.50, no.3, pp.188-194, 2020 (ESCI)
Article / Article
ISTANBUL JOURNAL OF PHARMACY
Emerging Sources Citation Index (ESCI)
Citalopram, hepatotoxicity, hepatic biomarker, liver histology, oxidative status, INDUCED LIVER-INJURY, SEROTONIN REUPTAKE INHIBITORS, DRUG, ANTIDEPRESSANTS, ESCITALOPRAM, METABOLITES, MECHANISMS, DIAGNOSIS, PLACEBO
Anadolu University Affiliated:
Background and Aims: Citalopram is a selective serotonin reuptake inhibitor with a high potency which is occasionally prescribed and used to treat major depression associated with mood disorders as a first-line drug. According to the results of previous studies, evidence of hepatotoxicity related to citalopram treatment were limited and conflicting. Therefore, we aimed to evaluate the hepatotoxicity potential of sub-chronic citalopram administration.